MHT and breast cancer: facts, figures, and what the science really says

The fear of breast cancer is the primary reason women refuse or delay MHT, even when experiencing severe menopausal symptoms. This fear is understandable, but it is based on outdated information and a study with serious methodological limitations.

This article provides an honest, evidence-based overview. We are not downplaying the issue—breast cancer is a serious disease that deserves careful discussion—but we are addressing the unnecessary fear based on obsolete evidence.

Where the fear comes from: the 2002 WHI study

In 2002, the Women's Health Initiative (WHI) published a study that shocked the world: women using hormone therapy had an increased risk of breast cancer. Doctors stopped prescribing it, women stopped taking it in droves, and the fear that emerged then persists to this day.

However, the study had fundamental limitations that significantly affect its interpretation:

• The participants were on average 63 years old —starting hormone therapy ten to twelve years after menopause
• They used oral estrogen (conjugated equine estrogens) in combination with the synthetic progestogen MPA (medroxyprogesterone acetate)
• It did not involve bioidentical hormones administered transdermally
• A significant portion of the participants already had an elevated baseline risk of breast cancer before the study began

The results apply to that specific combination in that specific population. They do not apply to transdermal MHT with bioidentical progesterone in women who start early.

What science has shown since then

The type of progestogen makes a crucial difference. This is the most consistent finding in the literature since 2002. Synthetic progestogens—such as MPA—have been associated with an increased risk of breast cancer in multiple studies. Bioidentical progesterone is not.

The large French ESTHER study and the E3N cohort study (more than 80,000 women, followed for over ten years) consistently show that women who used bioidentical progesterone had no increased risk of breast cancer—even with long-term use. The French experience with bioidentical progesterone spans more than 30 years.

The method of administration makes a difference. Unlike oral estrogen, transdermal estradiol has no significant effect on breast tissue via the bloodstream. Studies show that transdermal estradiol combined with bioidentical progesterone has a favorable risk profile.

Timing is important. Starting early—within ten years of menopause—has a neutral to favorable risk profile. This is also the window in which BHRT has the most protective effects on the heart and bones.

The absolute risk in perspective

Even the WHI study—using the least favorable type of hormone therapy—found an absolute risk of less than one additional case of breast cancer per 1,000 women per year. This is comparable to the risk associated with two glasses of alcohol per day, or a BMI over 30.

This does not mean that risk is unimportant. But it does mean that it must be kept in perspective. Women weigh risks every day—in diet, exercise, alcohol—without dramatizing them. The risk of untreated severe menopausal symptoms—for bone density, heart health, cognition, and quality of life—is also real and measurable.

When is BHRT not suitable due to breast cancer?

There are situations where caution is advised:

• Active breast cancer: systemic BHRT is contraindicated during active treatment
• History of hormone receptor-positive breast cancer: this is the most complex situation — consultation with an oncologist is always required here. Local estrogen therapy for vaginal symptoms is often possible.
• Strongly elevated familial risk (BRCA1/2): this is a relative contraindication — decision-making is individual and requires genetic counseling

Women without a history of breast cancer and without a strongly elevated genetic risk do not need to decline BHRT based on fear alone. The risk profile of transdermal estradiol plus bioidentical progesterone is favorable for them.

BHRT and breast cancer screening

Using BHRT is no reason to skip population screening (mammography) — on the contrary. Regular screening is just as important for women using BHRT as it is for those who do not. BHRT can slightly increase breast tissue density, which makes mammograms slightly more difficult to interpret. The radiologist will be informed of this so that the assessment can take it into account.

Talking to your doctor

The decision regarding BHRT is always individual. Your personal risk profile — family history, age, BMI, lifestyle, severity of symptoms — determines the balance. A doctor specializing in hormonal health can help you weigh these factors based on current science, not on fears from 2002.

At Menovia we discuss breast cancer risk as a standard part of the intake — honestly, thoroughly, and based on current evidence. If there are contraindications, we will tell you. If BHRT is safe and beneficial for you, we will explain that as well. Read more about our approach.

Summary

The fear of breast cancer surrounding BHRT is largely based on the 2002 WHI study — a study using the wrong type of hormones, the wrong method of administration, and the wrong age group. For transdermal estradiol combined with bioidentical progesterone — the combination used by Menovia — the science shows a significantly more favorable picture. For most women, the risk is comparable to other daily lifestyle choices and must be weighed against the significant benefits of treatment.